BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17342095)

  • 21. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
    Peca C; Pacelli R; Elefante A; Del Basso De Caro ML; Vergara P; Mariniello G; Giamundo A; Maiuri F
    Clin Neurol Neurosurg; 2009 May; 111(4):331-4. PubMed ID: 19117668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of an adenosine A
    Jackson S; Weingart J; Nduom EK; Harfi TT; George RT; McAreavey D; Ye X; Anders NM; Peer C; Figg WD; Gilbert M; Rudek MA; Grossman SA
    Fluids Barriers CNS; 2018 Jan; 15(1):2. PubMed ID: 29332604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
    Schaich M; Kestel L; Pfirrmann M; Robel K; Illmer T; Kramer M; Dill C; Ehninger G; Schackert G; Krex D
    Ann Oncol; 2009 Jan; 20(1):175-81. PubMed ID: 18687982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
    Watanabe R; Nakasu Y; Tashiro H; Mitsuya K; Ito I; Nakasu S; Nakajima T
    Brain Tumor Pathol; 2011 Apr; 28(2):127-35. PubMed ID: 21331613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
    Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
    Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
    Kim J; Lee IH; Cho HJ; Park CK; Jung YS; Kim Y; Nam SH; Kim BS; Johnson MD; Kong DS; Seol HJ; Lee JI; Joo KM; Yoon Y; Park WY; Lee J; Park PJ; Nam DH
    Cancer Cell; 2015 Sep; 28(3):318-28. PubMed ID: 26373279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
    Binello E; Germano IM
    J Neurooncol; 2009 Aug; 94(1):145-8. PubMed ID: 19199004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
    Nabors LB; Mikkelsen T; Hegi ME; Ye X; Batchelor T; Lesser G; Peereboom D; Rosenfeld MR; Olsen J; Brem S; Fisher JD; Grossman SA;
    Cancer; 2012 Nov; 118(22):5601-7. PubMed ID: 22517399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
    Combs SE; Gutwein S; Schulz-Ertner D; van Kampen M; Thilmann C; Edler L; Wannenmacher MM; Debus J
    Strahlenther Onkol; 2005 Jun; 181(6):372-7. PubMed ID: 15925979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.